Author: devcuration

BlueNalu never chased volume. It chased value, patience, and physics. In an industry that treats seafood like a commodity until the ocean sends the invoice, this San Diego company aimed straight at the most unforgiving cut on the menu: bluefin tuna toro. The kind chefs guard. The kind markets ration. The kind that exposes pretenders fast. You do not touch toro unless your science, supply chain, and economics can all sit at the same table without flinching. January 2026 arrives with BlueNalu closing an $11M insider-led financing, structured across convertible notes and preferred stock, led by Agronomics, Siddhi Capital, and…

Some problems in banking scream for attention. Others just sit there, quietly dragging deals into the mud while everyone shrugs and calls it “process.” Commercial account switching has lived in that second category for decades. Not broken enough to spark revolt. Painful enough to cost real money. Onsetto exists because Cale Johnston has already seen what happens when friction gets ignored, solved, sold, and then politely forgotten by the market. Minneapolis has a habit of producing builders who do not chase volume; they chase leverage. Onsetto was founded in 2025 by Cale Johnston after scaling ClickSWITCH into an industry standard…

There is a moment in every industry when the noise drops and the signal gets loud. Healthcare is in one of those moments, and Apella just turned the volume knob with an $80M Series B that feels less like a raise and more like a declaration. Founded in 2019 and based in San Francisco, Apella is doing the unglamorous work that actually moves the needle: making operating rooms run on truth instead of gut feel. Ambient AI, computer vision, and real-time operational intelligence quietly watching the room, learning the room, and giving hospitals back the rarest asset they have, which…

Valinor Enterprises did not show up to chase headlines. It showed up to chase problems the rest of the market keeps stepping over. Founded in 2024 and built out of Washington, D.C., Valinor is an operating holding company in the original sense of the word. It holds reality. The kind operators deal with when connectivity drops, supply chains crack, and the mission still does not care. Julie Bush built this after more than a decade inside Palantir and time on Capitol Hill, alongside Paul Kwan, Trae Stephens, and Grant Verstandig, four people who know exactly where theory dies and execution…

In 2017, while most of Silicon Valley was busy optimizing clicks and dopamine loops, Blackbird.AI took a quieter, sharper flight path. Founded by Wasim Khaled and Dr. Naushad UzZaman, two computer scientists who understood the next real threat would not crash servers but crash trust, the company set out to confront narrative attacks before the term showed up in board decks. Computational propaganda, info ops, synthetic amplification. Not theory. Not vibes. Real forces already bending markets, elections, and reputations in plain sight. Blackbird.AI secured a $28M strategic investment, bringing total capital raised to $58M. The round was led by Ten…

Insurance has always been the quiet room where innovation goes to wait. Paper forms. Annual cycles. Brokers translating yesterday’s risk for tomorrow’s companies. Corgi walked into that room like a corgi puppy with a badge and a mission, tail wagging, teeth sharp, knocking over the furniture with intent. AI-native. Full-stack carrier. Built in San Francisco in 2024 for companies that move at cloud speed and think in commits, not calendar years. This is not software taped onto insurance. This is insurance built for velocity. Nicolas S. Laqua and Emily Yuan did not come up through actuarial hallways, and that is…

Medical imaging is the heavyweight champ of healthcare data. Over 80% of it lives in pixels, scans, slices, and signals, yet most of the industry still treats it like loose film reels stacked in a forgotten basement. Flywheel shows up and says no, this data deserves infrastructure, discipline, and systems built for adults in the room. The market agreed with a $25M oversubscribed equity round led by Novalis LifeSciences and 8VC, backed by a lineup that reads less like hype and more like proof: NVentures at NVIDIA, Microsoft, Novartis, Intuitive Surgical, Hewlett Packard Enterprise, Beringea, Great North Ventures, iSelect, Gundersen…

Sirion just inked a deal that reads less like a funding announcement and more like a thesis on where enterprisesoftware is finally growing up. A majority investment from Haveli Investments, valuing Sirion at roughly $1B. Not hype math. Grown-up math. The kind that only shows up after a decade of building, breaking, fixing, and scaling inside the parts of the enterprise most people pretend are “handled.” Contracts rarely are. Ajay Agrawal did not wake up one morning chasing AI headlines. Ajay Agrawal lived inside the mess at UnitedLex and saw contracts treated like static PDFs instead of economic engines. Sirion…

January 8, 2026 did not read like a victory lap. It read like alignment. Protege secured a $30M Series A extension led by Andreessen Horowitz, bringing total capital raised to $65M since launching in 2024. No theatrics. No chest pounding. Just capital moving toward infrastructure that has already proven it belongs in the center of the AI economy. Protege operates where the real friction lives. Data that is regulated, licensed, governed, and actually usable. The kind of data that trains models without blowing up reputations or compliance teams. Headquartered in New York City, the company was founded by Bobby Samuels,…

Diagonal Therapeutics just closed an oversubscribed $125M Series B, and this is not one of those biotech headlines floating on vibes, deck aesthetics, and hope. This is what happens when computation, biology, and restraint stop posturing and start agreeing. Watertown, Massachusetts keeps proving that the loudest breakthroughs rarely raise their voice. They just show the data and wait. Founded in 2022 by Alexey Lugovskoy, Ph.D., alongside Atlas Venture, Diagonal Therapeutics emerged from stealth in April 2024 with a $128M Series A and a very specific opinion about signaling. Most antibodies shut things down. Diagonal activates, clusters, and restores. Digital. Agonist.…